Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13), Zacks reports.
Unicycive Therapeutics Stock Performance
NASDAQ:UNCY opened at $0.61 on Monday. Unicycive Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.60. The stock has a fifty day moving average of $0.59 and a 200 day moving average of $0.57. The firm has a market capitalization of $63.73 million, a price-to-earnings ratio of -0.63 and a beta of 2.26.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 price target on shares of Unicycive Therapeutics in a research report on Wednesday, January 29th.
Unicycive Therapeutics Company Profile
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Featured Articles
- Five stocks we like better than Unicycive Therapeutics
- What Are the FAANG Stocks and Are They Good Investments?
- Lululemon Pulls Back Into Classic Dip-Buying Opportunity
- Should You Invest in Penny Stocks?
- Cintas Delivers Earnings Beat, Signals More Growth Ahead
- How to Evaluate a Stock Before BuyingÂ
- Analysts Say These 4 Low P/E Consumer Cyclical Stocks Are Buys
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
